Audio Interview

SARS-CoV-2 vaccine development: where are we now?

Published on April 6, 2020   12 min

Other Talks in the Playlist: Interviews on Covid-19

Please wait while the transcript is being prepared...
Interviewer: Professor Kobinger, thank you very much for taking the time today to record this interview about where we currently stand in the development of a vaccine for the SARS-CoV-2 virus. Could you firstly give us an overview of where we currently stand on vaccine development? Prof. Kobinger: Yes, the overview on vaccine development is not that easy in the sense that I'm one person, I don't know everything in the field in real time. That being said, I know a fair amount and I will share this with you. We're seeing a lot of different possibilities, we use the words 'vaccine platforms' which means different vaccines or vaccine strategies, it could be the same vaccine but for example, with or without adjuvants or different regimens (say one, two or three doses). What's happening right now in terms of a high-level overview: there is one vaccine based on RNA that entered clinical trials last week or two weeks ago in the US, there is another vaccine based on DNA set to enter clinical trials this month, which is pending approval from the FDA (the Food and Drug Administration), so it's their decision. They could say 'not this Monday but the following one', from what I'm hearing it should start before the end of April. There is a lot of effort, notably in Europe from CEPI, that is funding many different vaccines and vaccine strategies. The DNA vaccine that I just talked about is one of them, but there are more: Johnson & Johnson also has a vaccine that is advancing, they said publicly yesterday (or the day before) that they were going

SARS-CoV-2 vaccine development: where are we now?

Embed in course/own notes